

AD-A096 358


CINCINNATI UNIV OH COLL OF MEDICINE  
ADDITIONAL STUDIES ON METABOLISM OF WR-158,122 IN RATS AND MONK--ETC(U)  
MAR 81 C C SMITH, M W TABOR, G F WOLFE

F/6 6/15  
DAMD17-79-C-9106

NL

UNCLASSIFIED

1 OF 1  
AD A  
096358



A  
963

LEVEL II

40

2

Unclassified

AD

9 Interim Report No. 5, 15 May 80 - 20 Jan 81,

6 Additional Studies on Metabolism of WR-158,122  
in Rats and Monkeys •

10  
Carl C. Smith, Ph.D.  
M. Wilson/Tabor, Ph.D.  
Geraldine F./Wolfe, M.S.

Steele F./Mattingly, D.V.M.  
David H./Bauman, D.V.M.  
Gary L. Keller, D.V.M.

DTIC  
ELECTE  
MAR 16 1981

February 12, 1981  
Revised March 10, 1981

Supported by

U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND  
Fort Detrick, Frederick, Maryland 21701

15  
Contract No. DAMD17-79-C-9106

Department of Environmental Health and  
Department of Laboratory Animal Medicine  
University of Cincinnati College of Medicine  
Cincinnati, Ohio 45267

DDC Distribution Statement

Approved for public release; distribution unlimited.  
The findings in this report are not to be construed  
as an official Department of the Army position unless  
so designated by other authorized documents.

Unclassified

AD A 096358

DDC FILE COPY

083800

81 3 13 015

Unclassified

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

| REPORT DOCUMENTATION PAGE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                | READ INSTRUCTIONS<br>BEFORE COMPLETING FORM                |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|
| 1. REPORT NUMBER<br>Interim Report No. 5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 2. GOVT ACCESSION NO.<br>AD-A096 358                                                                           | 3. RECIPIENT'S CATALOG NUMBER                              |
| 4. TITLE (and Subtitle)<br>Additional studies on metabolism of WR-158,122 in rats and monkeys                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 5. TYPE OF REPORT & PERIOD COVERED<br>Interim Report No. 5<br>May 15, 1980-Jan. 20, 1981                       | 6. PERFORMING ORG. REPORT NUMBER<br>Interim Report No. 5 ✓ |
| 7. AUTHOR(s)<br>Smith, Tabor, Wolfe, Mattingly, Bauman and Keller                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 8. CONTRACT OR GRANT NUMBER(s)<br>DAMD 17-79-C-9106 ✓                                                          |                                                            |
| 9. PERFORMING ORGANIZATION NAME AND ADDRESS<br>Department of Environmental Health and Department of Laboratory Animal Medicine. University of Cinti., College of Medicine, Cinti., Ohio 45267                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS<br>2102040 075-8119<br>612770.80300<br>2583 S18064 |                                                            |
| 11. CONTROLLING OFFICE NAME AND ADDRESS<br>U.S. Army Medical Research and Developmental Command.<br>Fort Detrick, Frederick, Maryland 21701                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 12. REPORT DATE Feb. 12, 1981<br>Revised March 10, 1981                                                        |                                                            |
| 14. MONITORING AGENCY NAME & ADDRESS (If different from Controlling Office)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 13. NUMBER OF PAGES<br>26                                                                                      |                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 15. SECURITY CLASS. (of this report)<br>Unclassified                                                           |                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 15a. DECLASSIFICATION/DOWNGRADING SCHEDULE                                                                     |                                                            |
| 16. DISTRIBUTION STATEMENT (of this Report)<br>Approved for public release, distribution unlimited. The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                |                                                            |
| 17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                |                                                            |
| 18. SUPPLEMENTARY NOTES<br><br><div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;"> <p>for -</p> <p>✓</p> </div> <div style="text-align: center;"> <p>for -</p> <p>✓</p> </div> <div style="text-align: center;"> <p>for -</p> <p>✓</p> </div> </div>                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                |                                                            |
| 19. KEY WORDS (Continue on reverse side if necessary and identify by block number)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                |                                                            |
| Rat<br>Monkey<br>bile duct cannulation<br>bile duct ligation<br>WR-158,122                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | sulfonyl quinazoline<br>urinary excretion<br>biliary excretion<br>fecal excretion                              | 2,4-diamino-6-(2-naphthyl-sulfonyl)-quinazoline            |
| 20. ABSTRACT (Continue on reverse side if necessary and identify by block number)<br><p>Blood levels, excretion and tissue distribution of WR-158,122 <sup>14</sup>C were studied in 10 bile duct ligated rats, 10 bile duct cannulated rats, 8 control rats and in 2 control and one bile duct cannulated monkeys. In 72 hours bile duct ligated rats excreted about 16.3 ± 3.8% as <sup>14</sup>C in the urine and the remaining <sup>14</sup>C was recovered primarily in the feces. About 2% was recovered in the carcass and tissues at necropsy. Bile duct cannulated rats excreted about 10.9 ± 6.1% in the bile, 2.3 ± 1.3% in the urine and the remainder in the feces. Only about 1.3 ± 1.0% was recovered in the carcass and tissues. Control rats</p> |                                                                                                                |                                                            |

Unclassified

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

excreted the compound rather rapidly;  $1.5 \pm 0.8\%$  of the  $^{14}\text{C}$  was recovered in the urine,  $0.3 \pm 0.2$  in the carcass and other tissues and the remainder in the feces. Total average recovery (as  $^{14}\text{C}$ ) in the three groups of rats varied from 94 to 100% of the dose. Two experiments were conducted in a single bile duct cannulated monkey. In the first the blood and plasma levels were highest at two hours after dosing. Plasma levels routinely exceeded levels in whole blood indicating little sequestration of WR-158,122 (as  $^{14}\text{C}$ ) in the red cells. Both levels were low at 24 hours and below detection at 48 hours. In this bile duct cannulated monkey biliary excretion over a 96 h. period accounted for 0.6 to 0.9% of the dose (as  $^{14}\text{C}$ ), urinary excretion for 3.1% and 87 to 95% of the dose was recovered in the feces. In two control monkeys urinary excretion over a 96 hour period amounted to 14 and 18%; 70% of the dose (as  $^{14}\text{C}$ ) was recovered in the feces. Excretion was essentially complete after 96 hours. In both rats and monkeys WR-158,122 appears to be rapidly but incompletely absorbed. Rats excreted 10% more in the bile but only 2-3% in the urine except in the case of bile duct ligated rats which excreted about 16% of the dose (as  $^{14}\text{C}$ ) in the urine.

|                    |                                            |
|--------------------|--------------------------------------------|
| Accession For      |                                            |
| NTIS GRA&I         | <input checked="checked" type="checkbox"/> |
| DTIC TAB           | <input type="checkbox"/>                   |
| Unannounced        | <input type="checkbox"/>                   |
| Justification      |                                            |
| By                 |                                            |
| Distribution/      |                                            |
| Availability Codes |                                            |
| Dist               | Avail and/or<br>Special                    |
| A                  |                                            |

Unclassified

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

## TABLE OF CONTENTS

|                           | <u>Page</u> |
|---------------------------|-------------|
| DD Form 1473              |             |
| List of Tables            | iii         |
| I. Introduction           | 1           |
| II. Materials and Methods | 2           |
| III. Results              | 5           |
| IV. Discussion            | 9           |
| V. Summary                | 11          |
| VI. Tables                | 13-24       |
| VII. Signature Page       | 25          |
| VIII. Distribution Page   | 26          |


# List of Tables

| <u>Table</u> |                                                                                                                                    | <u>Page</u> |
|--------------|------------------------------------------------------------------------------------------------------------------------------------|-------------|
| 1            | Excretion of WR-158,122 in Bile Duct Ligated Rats<br>Single Oral Dose of 10 mg/kg                                                  | 13          |
| 2            | Recovery of WR-158,122 in Bile Duct Ligated Rats<br>Single Oral Dose of 10 mg/kg                                                   | 14          |
| 3            | Excretion of WR-158,122 in Bile Duct Cannulated<br>Rats Single Oral Dose of 10 mg/kg                                               | 15          |
| 4            | Recovery of WR-158,122 from Bile Duct Cannulated<br>Rats Single Oral Dose of 10 mg/kg                                              | 16          |
| 5            | Excretion of WR-158,122 in Control Rats Single<br>Oral Dose of 10 mg/kg                                                            | 17          |
| 6            | Recovery WR-158,122 from Control Rats Single Oral<br>Dose of 10 mg/kg                                                              | 18          |
| 7            | Recovery of WR-158,122 (as <sup>14</sup> C) in Bile Duct Ligated<br>Bile Duct Cannulated and Control Rats                          | 19          |
| 8            | SMA 12/60 Assays on a Bile Duct Cannulated Monkey Prior<br>to Treatment with WR-158,122 <sup>14</sup> C                            | 20          |
| 9            | Blood and Plasma Levels of WR-158,122 (as <sup>14</sup> C) in a<br>Bile Duct Cannulated Monkey (75-5 ♀)                            | 21          |
| 10           | Cumulative Excretion of WR-158,122 (as <sup>14</sup> C) in Bile,<br>Urine and Feces from a Bile Duct Cannulated Monkey<br>(75-5 ♀) | 22          |
| 11           | SMA 12/60 Results on Two Control Monkeys Before<br>Treatment                                                                       | 23          |
| 12           | Cumulative Excretion of WR-158,122 in Urine and Feces<br>of Two Control Monkeys, Single Oral Doses of 5 mg/kg                      | 24          |

Interim Report No. 5

Introduction

Studies on the metabolic fate of WR-158,122 [2, 4-diamino-6-(2 naphthylsulfonyl)-quinazoline-2-<sup>14</sup>C], the antifolate antimalarial compound shown below



have been carried out in 3 rhesus monkeys, 10 bile-duct cannulated rats, 10 bile-duct ligated rats and 8 controls rats. Data on excretion and residual tissue distribution in rats and blood level data and excretion in monkeys are detailed in this report.

## MATERIALS AND METHODS

Compounds. WR-158,122 [2,4-diamino-6-(2-naphthylsulfonyl)-quinazoline-2- $^{14}\text{C}$ ], empirical formula  $\text{C}_{18}\text{H}_{14}\text{SO}_2\text{N}_4$ , mol. wt. 350, was supplied by Walter Reed unlabeled as Bottle AY 65859. The  $^{14}\text{C}$ -labeled preparation was synthesized by Research Triangle Institute and dated 1/8/79. Lot No. 2572-110, dated 8/20/79, has a specific activity of 69  $\mu\text{Ci}/\text{mg}$  or 24  $\text{mCi}/\text{mmole}$ . The radiochemical purity in a number of TLC systems was  $> 98\%$ .

Treatment Suspension. A typical treatment suspension was prepared as follows: 307.13 mg cold drug and 3.08 mg of  $^{14}\text{C}$  labeled drug were ground intimately in a glass mortar with glass pestle with addition of small amounts of diluent (0.2% methylcellulose and 0.4% Tween 80 in distilled water) until a smooth suspension was achieved. The suspension was decanted into a tared round-bottom polycarbonate 200 ml centrifuge bottle containing glass beads and diluted to 124.08 ml. It contained 2.50 mg WR-158,122/ml and 1.86  $\mu\text{Ci}/\text{ml}$ . The suspension was stored at  $4^\circ\text{C}$ . Assay of this suspension gave the following results:

4,136,000 dpm/ml  
1654 dpm/ $\mu\text{g}$   
1.86  $\mu\text{Ci}/\text{ml}$

Other preparations with approximately the same activity were prepared in the same manner.

## Analytical Procedures.

Blood samples were analyzed for total  $^{14}\text{C}$  content as described in Interim Report No. 2. Urine samples from rats or monkeys were counted in Biofluor<sup>®</sup> (New England Nuclear Corp.). Feces were assayed in a few instances by the total sample digestion procedure described in Interim Report No. 1. Because we wished to identify fecal metabolites as well as measure total  $^{14}\text{C}$

content, most samples were milled in a stainless steel jar with stainless steel balls according to the procedure developed in this laboratory and described in detail in Interim Report No. 4. In brief, the samples were ground in the ball mill for 30 min. with 4 to 8 parts of anhydrous  $\text{Na}_2\text{SO}_4$ . Aliquots of the resulting fine off-white powder (250 mg) were digested for 48 hrs. with 1 ml of Soluene<sup>®</sup> (Packard Instrument Co.) and after bleaching with 0.5 ml of t-butyl hydrogen peroxide were counted in Biofluor. All samples were initially cooled and dark adapted and were internally standardized to determine efficiency.

The carcasses and other tissues (either separately in some cases or as a unit in others) were counted as described previously. The bones do not dissolve in the alkaline digestion procedure employed. However, digestion with Soluene<sup>®</sup> of the dried finely powdered bones from some representative rats yielded counts equivalent only to 0.01% of the dose. Extraction of the bone powder with tetrahydrofuran recovered even smaller amounts of drug (as  $^{14}\text{C}$ ). Based on these findings no further work on bone  $^{14}\text{C}$  has been done.

#### Animals.

Rats. Sprague-Dawley-derived rats weighed 244 to 305 g (bile duct ligated), 260 to 400 g (bile duct cannulated) and 365 to 410 g (control rats) at the time of treatment. The bile duct ligated rats were prepared as described in Interim Report No. 1 and housed in metabolism cages. The bile duct cannulated rats, prepared essentially as described in Interim Report No. 1, were restrained in a close fitting wire housing attached to the metal cover of a plastic cage. Food and water were supplied ad libitum four hours after dosing. Urine and feces were separated using a bottle equipped with a funnel and woven wire separator. Bile was collected in a

tared vial.

Bile, urine and feces were collected usually at 12, 24, and 48 h. At 48 h. or 72 h. the rats were necropsied using an anesthetic dose of Nembutal<sup>®</sup>. In a number of instances the tissues were assayed for <sup>14</sup>C in three sections: 1) tissues (liver, heart, lungs, spleen and kidneys as a pool); 2) gastrointestinal tract and contents; 3) carcass. However, these analyses have been reported as a single item, "carcass with all tissues", since with rare and usually unexplained exceptions these three tissue groups accounted for no more than about 2% of the dose.

Ten bile duct ligated rats were prepared and all are reported. Of the 20 bile duct cannulated that were prepared only 10 are reported. Four died prematurely; 3 exhibited unacceptably low recovery; two had large amounts of drug in the GI tract not characteristic of any of the other animals in the group; and one was eliminated because it had unaccountably large amounts of <sup>14</sup>C in the carcass.

Twelve control rats were given WR-158,122 but only 8 are reported. Three were deleted because of low recovery (50 to 60%) of the <sup>14</sup>C dose. The basis for these poor recoveries has not been established. One was eliminated because about half the dose was present in the carcass whereas the other carcass values were well below 1%.

Monkeys. Two unoperated rhesus monkeys (# 1449<sup>♀</sup> and # 709<sup>♀</sup>) were administered WR-158,122 while in a primate chair. Both animals required supplemental feeding, possibly due to the stress associated with the restraint.

The bile duct cannulated monkey (75-5<sup>♀</sup>) was acclimated to a primate chair for considerable periods prior to surgery. The cannulation was accomplished under Ketamine<sup>®</sup>-Surital<sup>®</sup> anesthesia following a 24 h fast. Blood chemistries

and CBC were done on a blood sample obtained at the time of the operation. After the operation the animal was given Flocillin<sup>®</sup> (1 ml BID) and intravenous fluids. When no bile flow occurred on day 4 surgery was repeated. Following a two week period during which the animal required considerable support in the form of bile, fluids and liquid diet given via nasal catheter or duodenal tube, the animal's bile flow became more consistent. On the twentieth day following the second operation, the animal was given a single oral dose of WR-158,122. During the post treatment period saline was slowly infused via the duodenal tube and the animal's bile was replaced with about equal amounts of beef bile. Blood samples were obtained from the left or right antecubital veins at 2, 4, 6, 8, 12, 24, 48 and 72 hours after treatment. Bile production and feces and urine excretion were excellent during this period.

A second dose of WR-158,122 was administered at 4 days. During the second post-operative period the animal also required supportive fluids and beef bile but bile, urine and feces production was good during this period.

### Results

Bile Duct Ligated Rats. The excretion of single oral doses of labelled WR-158,122 in 10 bile duct ligated rats is shown in Table 1. Urinary excretion varied from 11 to 21% and was essentially complete at the end of 48 hours. Fecal excretion varied from 74 to 93 per cent of the dose. The high value for total recovery in BL-10 is probably due to an undetected error in measuring the treatment dose. As one would expect, the 4 rats sacrificed at 48 hours (BL-15 to BL-18) had more drug (1 to 11%) in their tissues at necropsy than the remaining animals killed after 72 hr (0.3 to 0.7%) (see Table 2), but most of the drug was cleared from the rat's body by 72 hr. Additional

comments on these data will occur later in the report.

Bile Duct Cannulated Rats. The excretion of single oral doses of labeled WR-158,122 in 10 bile duct cannulated rats is described in Table 3. Biliary excretion (as  $^{14}\text{C}$ ) varied rather widely from 2.5 to 23.6%. This variation may reflect the adequacy of biliary excretory processes but does not seem to depend on bile flow. By far the most active bile excretion occurred during the first 12 hours after treatment; the fraction of the total biliary excretion which occurred during this first period varied from 59 to 87%.

Urinary excretion of WR-158,122 (as  $^{14}\text{C}$ ) in bile duct cannulated rats accounted for from 0.8 to 4.2% of the dose, the majority of the radiolabel being excreted via this route usually appearing during the first 12 hours.

Fecal excretion of WR-158,122 (as  $^{14}\text{C}$ ) in bile duct cannulated rats varied from 64 to 94% of the dose. Excretion via this route occurred principally during the first 24 hr period and was essentially complete by 48 hours, as indicated by the finding that less than 1% of the dose was recovered in the GI tract and contents at 48 hours when the rats were necropsied.

The data on recovery of  $^{14}\text{C}$  in the carcass and tissues presented in Table 4 show that from 0.42 to 3.45% of the dose was still in the body at the end of 48 hours. As a rule the amount of drug (as  $^{14}\text{C}$ ) in the body at this time was 1% or less, clearance of drug from the body being essentially complete by 48 hours.

Control Rats. The parallel results obtained in 8 control rats are shown in Tables 5 and 6. The kinetics of excretion were essentially the same as observed in bile duct ligated and bile duct cannulated rats. Urinary excretion accounted for 0.8 to 2.9% of the  $^{14}\text{C}$  administered and occurred primarily (68 to 91%) during the first 12 hours.

Fecal excretion (as  $^{14}\text{C}$ ) accounted for from 91 to 109% of the dose, the principal portion occurring during the first 24 hours.

The drug content (as  $^{14}\text{C}$ ) of the carcass at 48 hours never accounted for more than about 0.5% of the dose. This finding further supports the suggestion that in rats WR-158,122 is rapidly cleared from the body after single oral doses.

If we compare data in bile duct ligated, bile duct cannulated and control rats (Table 7) one is led to some interesting conclusions. Comparison of the data on urinary excretion of WR-158,122 in bile cannulated rats with the data in control (unoperated) rats suggests that about equal amounts of the drug undergo urinary excretion whether the bile duct is cannulated or not. If the duct is ligated, however, considerably more  $^{14}\text{C}$  appears in the urine (16%). These findings suggest that at least 13 to 16% of the dose must be absorbed, some being excreted in the urine (1.6-2.3%), the rest in the bile. The assumption that the livers of these bile duct ligated and bile duct cannulated animals may not be functioning as well as in unoperated animals suggests that perhaps even more of the dose normally undergoes absorption and biliary excretion. The fact that the drug is cleared rapidly from the GI tract (data obtained but not shown) suggests that that portion of the drug undergoing biliary excretion is not reabsorbed. Perhaps the only metabolites excreted in the bile are conjugates too polar to be reabsorbed.

#### Monkeys

Although biliary cannulation was carried out in four monkeys, only one (75-5<sup>9</sup>) survived for sufficient time to permit metabolism studies. No pertinent reasons have been discovered to account for this rather poor survival

record. In Table 8 blood chemistries on 75-5<sup>9</sup> at the time of initial surgery and at two periods thereafter are compared with normal values. The animal had high levels of LDH and alkaline phosphatase and slightly elevated SGOT even before surgery; values for other parameters were close to normal values.

Following a single oral dose of WR-158,122 (5 mg/kg), the highest blood or plasma level occurred at 2 hours; then the levels fell to almost insignificant values by 24 hours and were below the level of detection thereafter (Table 9). Because of the stress associated with collecting blood samples in this monkey, blood levels were not determined during the second treatment period.

Excretion of WR-158,122 (as <sup>14</sup>C) in bile, urine and feces following two single oral doses of WR-158,122 are detailed in Table 10. Recovery of drug (as <sup>14</sup>C) in bile was quite low, equal to less than 1% of the dose. About 3% was recovered in the urine and the remainder in the feces. Comments on these data appear in the discussion.

Two unoperated monkeys were used to evaluate the absorption and excretion of WR-158,122. The clinical chemistry findings (SMA 12/60) compared with results in a group of 20 healthy female rhesus monkeys studied by the same laboratory but housed in another building are shown in Table 11. Except for the elevated LDH values for which we have no explanation, these two female animals appeared to be relatively normal, as judged by these data.

The excretion of WR-158,122 (as <sup>14</sup>C) in these two female animals following single oral doses of 5 mg/kg are shown in Table 12. It is interesting that although total recovery of <sup>14</sup>C amounted to only 84 to 87%, from 14 to 18% of the <sup>14</sup>C appeared in the urine, the remainder in the feces.

## Discussion

It is interesting to compare the data in this Interim Report with the results we obtained previously in Interim Report No. 1. In rats with bile duct ligation, the greatest difference appeared in fecal recovery (81.5% in current group versus 67.8% in the Interim Report No. 1 group) and higher total recovery (99.9% in Interim 5 versus 88.4% in Interim 1).

Excretion in bile was slightly greater in the early group of bile-duct cannulated rats. In the bile duct cannulated rats there was a greater disparity between the two groups of animals. Thus we recovered almost 30% of the dose of WR-158,122 in the bile in the Interim 1 group but only 11% in the current series. The simplest explanation for this discrepancy might be that the bile duct cannulae appeared to function better in the first group of rats. Comparison of the kinetics of biliary excretion in the two groups indicates another striking difference. In the first group of six rats (Interim 1) the peak excretion of  $^{14}\text{C}$  in the bile occurred in the 12-24 hr. sample in 3 rats, in the 24-48 hr sample in 2 rats and in the 0-12 hr sample in only 1 rat. In contrast, in the 10 rats included in this interim report all of the rats gave maximum values for biliary excretion in the 0-12 hr period after which the excretion rates dropped rather rapidly in most instances. The basis for this difference has not been ascertained but one would reason that if the biliary cannulae are functioning well excretion via this route would be greater than in a group of rats with less well functioning biliary cannulae. Perhaps we need additional criteria on which to evaluate the adequacy of the cannulation procedure.

The monkey data suffer from their paucity as well as from the general comment that the data in this one bile duct cannulated monkey are probably

not very representative of data one should expect in healthy monkeys with adequate biliary cannulae. Thus one would expect that the total excretion of WR-158,122 ( $^{14}\text{C}$ ) in bile and urine in monkeys with well functioning bile duct cannulae should at least equal the urinary excretion of the drug in intact monkeys. If the drug is excreted in the bile as a non-reabsorbable metabolite then combined urine and biliary excretion in bile duct cannulated animals could very well exceed the urinary levels observed in intact animals. However, such has not been our experience to date and this suggests that the biliary cannulation technique needs improvement.

It might be worth commenting in this connection that urinary excretion of  $^{14}\text{C}$  in control rats given single oral doses of WR-158,122- $^{14}\text{C}$  was about one order of magnitude less than the corresponding figures in either bile duct ligated rats or bile duct cannulated rats (when in the latter one adds the biliary excretion to the urinary values). The best explanation of this would appear to be that the rat excretes WR-158,122 as metabolites (conjugates) in the bile that are unable to be reabsorbed from the gut.

In the unoperated monkey, urinary excretion levels are about 10 times as high as in the rat and this suggests either that the total metabolites excreted in the bile are considerably less in the monkey than in the rat or that the form in which the monkey excretes the compound in the bile is much more readily reabsorbed and excreted in the urine.

### Summary

1. Blood levels, excretion and tissue distribution of WR-158,122  $^{14}\text{C}$  were studied in 10 bile duct ligated rats, 10 bile duct cannulated rats, 8 control rats and in 2 control and one bile duct cannulated monkeys.
2. In 72 hours bile duct ligated rats excreted about  $16.3 \pm 3.8\%$  as  $^{14}\text{C}$  in the urine and the remaining  $^{14}\text{C}$  was recovered primarily in the feces. About 2% was recovered in the carcass and tissues at necropsy.
3. Bile duct cannulated rats excreted about  $10.9 \pm 6.1\%$  in the bile,  $2.3 \pm 1.3\%$  in the urine and the remainder in the feces. Only about  $1.3 \pm 1.0\%$  was recovered in the carcass and tissues.
4. Control rats excreted the compound rather rapidly;  $1.5 \pm 0.8\%$  of the  $^{14}\text{C}$  was recovered in the urine,  $0.3 \pm 0.2$  in the carcass and other tissues and the remainder in the feces.
5. Total average recovery (as  $^{14}\text{C}$ ) in the three groups of rats varied from 94 to 100% of the dose.
6. Two experiments were conducted in a single bile duct cannulated monkey. In the first the blood and plasma levels were highest at two hours after dosing. Plasma levels routinely exceeded levels in whole blood indicating little sequestration of WR-158,122 (as  $^{14}\text{C}$ ) in the red cells. Both levels were low at 24 hours and below detection at 48 hours.
7. In this bile duct cannulated monkey biliary excretion over a 96 h. period accounted for 0.6 to 0.9% of the dose (as  $^{14}\text{C}$ ), urinary excretion for 3.1% and 87 to 95% of the dose was recovered in the feces.
8. In two control monkeys urinary excretion over a 96 hour period amounted

to 14 and 18%; 70% of the dose (as  $^{14}\text{C}$ ) was recovered in the feces.

Excretion was essentially complete after 96 hours.

9. In both rats and monkeys WR-158,122 appears to be rapidly but incompletely absorbed. Rats excreted 10% more in the bile but only 2-3% in the urine except in the case of bile duct ligated rats which excreted about 16% of the dose (as  $^{14}\text{C}$ ) in the urine.

Table 1

Excretion of WR-158,122 in Bile Duct Ligated Rats  
Single Oral Dose of 10 mg/kg

| Sample        | Hours Post<br>Dose | Percent Dose Recovered as <sup>14</sup> C |                |                |                |                   |                |               |               |               |               |
|---------------|--------------------|-------------------------------------------|----------------|----------------|----------------|-------------------|----------------|---------------|---------------|---------------|---------------|
|               |                    | BL-9                                      | BL-10          | BL-11          | BL-12          | BL-13             | BL-14          | BL-15         | BL-16         | BL-17         | BL-18         |
| Urine<br>(ml) | 6                  | 1.4<br>(10.0)                             | 1.5<br>(7.2)   | 1.1<br>(10.0)  | 1.2<br>(9.9)   | 3.1<br>(11.3)     | 1.0<br>(10.2)  | *NC           | NC            | NC            | NC            |
|               | 12                 | 6.1<br>(10.3)                             | 5.5<br>(13.0)  | 7.4<br>(11.2)  | 4.9<br>(10.7)  | 6.0<br>(9.9)      | 5.1<br>(6.7)   | 5.8<br>(8.5)  | 6.5<br>(16.5) | 6.8<br>(14.0) | 6.6<br>(13.0) |
|               | 24                 | 3.9<br>(10.8)                             | 6.2<br>(12.4)  | 10.1<br>(10.2) | 6.1<br>(10.4)  | 7.0<br>(10.7)     | 1.5<br>(10.9)  | 5.3<br>(20.5) | 2.4<br>(31.5) | 5.6<br>(34.0) | 4.8<br>(14.0) |
|               | 48                 | 1.6<br>(27.5)                             | 6.7<br>(41.0)  | 2.0<br>(13.5)  | 4.4<br>(23.0)  | 4.4<br>(51.0)     | 5.1<br>(33.5)  | 1.6<br>(35.5) | 2.2<br>(35.5) | 5.7<br>(30.0) | 3.9<br>(30.5) |
| Total         | 72                 | 0.23<br>(15.0)                            | 0.83<br>(18.5) | 0.42<br>(16.5) | 0.59<br>(15.0) | 0.45<br>(10.5)    | 0.41<br>(15.0) | **SAC         | SAC           | SAC           | SAC           |
|               |                    | 13.2                                      | 20.7           | 21.0           | 17.2           | 21.0              | 13.1           | 12.7          | 11.1          | 18.1          | 15.3          |
| Feces<br>(g)  | 24                 | 79.1<br>(3.0)                             | 82.3<br>(3.8)  | 69.3<br>(5.1)  | 69.8<br>(3.3)  | 71.2<br>(4.9)     | 65.5<br>(4.7)  | 63.5<br>(3.3) | 84.3<br>(8.0) | 68.4<br>(6.6) | 60.7<br>(1.9) |
|               | 48                 | 5.2<br>(4.2)                              | 10.8<br>(5.9)  | 4.6<br>(5.5)   | 11.0<br>(2.6)  | 6.4<br>(4.0)      | 14.5<br>(3.7)  | 14.4<br>(2.8) | 2.1<br>(3.5)  | 12.0<br>(4.3) | 17.2<br>(1.6) |
|               | 72                 | 0.39<br>(4.8)                             | 0.23<br>(4.4)  | 0.10<br>(3.6)  | 1.5<br>(5.1)   | S.L. <sup>+</sup> | 1.0<br>(2.7)   | SAC           | SAC           | SAC           | SAC           |
|               | Total              | 84.7                                      | 93.3           | 74.0           | 82.3           | 77.6              | 81.0           | 77.9          | 86.4          | 80.4          | 77.9          |

\*NC = No collection

\*\*SAC = Sacrificed at 48 hrs.

<sup>+</sup> S.L. = Sample Lost

Table 2

Recovery of WR-158,122 in Bile Duct Ligated Rats  
Single Oral Dose of 10 mg/kg

|                             | Percent of Dose Recovered (as <sup>14</sup> C) in 48 or 72 Hours |       |       |       |       |       |        |        |        |        |
|-----------------------------|------------------------------------------------------------------|-------|-------|-------|-------|-------|--------|--------|--------|--------|
|                             | BL-9                                                             | BL-10 | BL-11 | BL-12 | BL-13 | BL-14 | *BL-15 | *BL-16 | *BL-17 | *BL-18 |
| Urine                       | 13.2                                                             | 20.7  | 21.0  | 17.2  | 21.0  | 13.1  | 12.7   | 11.1   | 18.1   | 15.3   |
| Feces                       | 84.7                                                             | 93.3  | 74.0  | 82.3  | 77.6  | 81.0  | 77.9   | 86.4   | 80.4   | 77.9   |
| Carcass with<br>all tissues | 0.36                                                             | 0.53  | 0.35  | 0.53  | 0.46  | 0.72  | 0.93   | 2.4    | 2.6    | 10.9   |
| Total                       | 98.3                                                             | 114.5 | 95.4  | 100.0 | 99.1  | 94.8  | 91.5   | 99.9   | 101.1  | 104.1  |

\*Sacrificed at 48 hours.

Table 3  
Excretion of WR-158, 122 in Bile Duct Cannulated Rats  
Single Oral Dose of 10 mg/kg

| Sample     | Hours Post Dose | Percent Dose Recovered as <sup>14</sup> C |             |            |             |             |              |              |              |             |             |
|------------|-----------------|-------------------------------------------|-------------|------------|-------------|-------------|--------------|--------------|--------------|-------------|-------------|
|            |                 | BC-13                                     | BC-14       | BC-15      | BC-17       | BC-18       | BC-21        | BC-22        | BC-23        | BC-24       | BC-26       |
| Bile (g)   | 12              | 16.3 (8.3)                                | 7.4 (6.7)   | 8.6 (6.8)  | 3.4 (8.3)   | 2.1 (8.2)   | 9.1 (10.1)   | 10.4 (8.8)   | 10.1 (7.8)   | 4.7 (7.4)   | 6.3 (7.7)   |
|            | 24              | 5.2 (8.0)                                 | 1.7 (13.5)  | 4.7 (6.4)  | 0.37 (3.7)  | 0.27 (7.3)  | 0.95 (9.1)   | 4.4 (8.9)    | 1.4 (7.0)    | 2.2 (10.2)  | 0.91 (8.3)  |
|            | 48              | 2.1 (17.9)                                | 0.52 (16.4) | 1.9 (13.6) | 0.32 (14.8) | 0.14 (16.8) | 0.40 (21.0)* | 0.68 (21.2)* | 0.60 (47.0)* | 1.1 (27.9)* | 0.48 (15.2) |
| Total      |                 | 23.6                                      | 9.6         | 15.2       | 4.1         | 2.5         | 10.5         | 15.5         | 12.1         | 8.0         | 7.7         |
| Urine (ml) | 12              | 1.5 (9.4)                                 | 1.3 (2.9)   | 1.1 (3.4)  | 0.60 (6.6)  | 0.39 (10.6) | 3.33 (13.2)  | 1.5 (8.8)    | 1.5 (10.8)   | 0.93 (15.8) | 1.0 (4.7)   |
|            | 24              | 0.68 (13.0)                               | 0.57 (15.6) | 2.1 (8.3)  | 0.13 (6.3)  | 0.08 (12.6) | 0.35 (6.3)   | 1.9 (10.2)   | 0.34 (9.0)   | 0.39 (11.8) | 0.16 (4.7)  |
|            | 48              | 0.31 (26.3)                               | 0.20 (17.6) | 1.0 (26.4) | 0.07 (12.6) | 0.15 (19.6) | 0.19 (57.0)  | 0.33 (54.0)  | 0.28 (41.0)  | 0.32 (25.2) | 0.13 (17.8) |
| Total      |                 | 2.5                                       | 2.1         | 4.2        | 0.80        | 0.62        | 3.9          | 3.7          | 2.1          | 1.6         | 1.3         |
| Feces (g)  | 24              | 54.4 (3.0)                                | 62.4 (6.5)  | 82.4 (2.2) | 63.2 (3.1)  | 82.4 (8.8)  | 88.5 (17.6)  | 78.8 (6.6)   | 68.3 (4.3)   | 81.3 (7.3)  | 71.9 (2.1)  |
|            | 48              | 10.0 (10.5)                               | 4.8 (14.3)  | 12.0 (9.0) | 15.6 (6.1)  | 1.4 (5.2)   | 1.7 (22.7)   | 3.6 (8.5)    | 7.1 (6.4)    | 3.9 (7.2)   | 20.4 (7.9)  |
| TOTAL      |                 | 64.4                                      | 67.2        | 94.4       | 78.8        | 83.8        | 90.2         | 82.4         | 75.4         | 85.2        | 92.3        |

\* Sample volume increased with water

Table 4

Recovery of WR-158,122 from Bile Duct Cannulated Rats  
Single Oral Dose of 10 mg/kg

|                             | Percent of Dose Recovered (as <sup>14</sup> C) in 48 Hours |       |       |       |       |       |       |       |       |       |  |
|-----------------------------|------------------------------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--|
|                             | BC-13                                                      | BC-14 | BC-15 | BC-17 | BC-18 | BC-21 | BC-22 | BC-23 | BC-24 | BC-26 |  |
| Urine                       | 2.5                                                        | 2.1   | 4.2   | 0.80  | 0.62  | 3.9   | 3.7   | 2.1   | 1.6   | 1.3   |  |
| Feces                       | 64.4                                                       | 67.2  | 94.4  | 78.8  | 83.8  | 90.2  | 82.4  | 75.4  | 85.2  | 92.3  |  |
| Bile                        | 23.6                                                       | 9.6   | 15.2  | 4.1   | 2.5   | 10.5  | 15.5  | 12.1  | 8.0   | 7.7   |  |
| Carcass with<br>all tissues | 1.37                                                       | 0.56  | 3.45  | 1.03  | 2.35  | 0.76  | 0.42  | 0.71  | 1.94  | 0.66  |  |
| Total                       | 91.9                                                       | 79.5  | 117.3 | 84.7  | 89.3  | 105.4 | 102.0 | 90.3  | 96.7  | 102.0 |  |

Table 5

Excretion of WR-158,122 in Control Rats  
Single Oral Dose of 10 mg/kg

| Sample        | Hours Post<br>Dose | Percent Dose Recovered as <sup>14</sup> C |                |                |                |                |                 |                |                |
|---------------|--------------------|-------------------------------------------|----------------|----------------|----------------|----------------|-----------------|----------------|----------------|
|               |                    | CT-1                                      | CT-2           | CT-3           | CT-4           | CT-8           | CT-9            | CT-11          | CT-12          |
| Urine<br>(ml) | 12                 | 1.7<br>(13.0)                             | 1.2<br>(4.7)   | 2.0<br>(11.0)  | 1.3<br>(8.0)   | 0.74<br>(8.8)  | 1.3<br>(8.8)    | 0.60<br>(7.5)  | 0.68<br>(6.1)  |
|               | 24                 | 0.73<br>(14.5)                            | 0.12<br>(8.0)  | 0.8<br>(10.8)  | 0.28<br>(13.0) | 0.06<br>(5.5)  | 0.38<br>(13.9)  | 0.07<br>(11.8) | 0.11<br>(10.3) |
|               | 48                 | 0.07<br>(31.0)                            | 0.03<br>(14.5) | 0.13<br>(24.0) | 0.04<br>(18.0) | 0.01<br>(7.1)  | 0.03<br>(19.4)  | 0.02<br>(32.0) | 0.03<br>(7.2)  |
| Total         |                    | 2.5                                       | 1.4            | 2.9            | 1.6            | 0.81           | 1.7             | 0.69           | 0.82           |
| Feces<br>(g)  | 24                 | 83.0<br>(7.3)                             | 95.9<br>(11.1) | 97.5<br>(11.1) | 90.8<br>(11.4) | 84.5<br>(13.1) | 107.3<br>(11.3) | 94.3<br>(11.2) | 90.4<br>(9.3)  |
|               | 48                 | 16.1<br>7.1                               | 2.8<br>(10.5)  | 2.8<br>(8.1)   | 6.5<br>(15.3)  | 6.1<br>(21.6)  | 1.3<br>(13.6)   | 1.4<br>(4.3)   | 5.0<br>(8.4)   |
|               | Total              | 99.1                                      | 98.7           | 100.3          | 97.3           | 90.6           | 108.6           | 95.7           | 95.4           |

Table 6

Recovery WR-158,122 from Control Rats  
Single Oral Dose of 10 mg/kg

|                             | Percent of Dose Recovered (as <sup>14</sup> C) in 48 Hours |       |       |      |      |       |       |       |
|-----------------------------|------------------------------------------------------------|-------|-------|------|------|-------|-------|-------|
|                             | CT-1                                                       | CT-2  | CT-3  | CT-4 | CT-8 | CT-9  | CT-11 | CT-12 |
| Urine                       | 2.5                                                        | 1.4   | 2.9   | 1.6  | 0.81 | 1.7   | 0.69  | 0.82  |
| Feces                       | 99.1                                                       | 98.7  | 100.3 | 97.3 | 90.6 | 108.6 | 95.7  | 95.4  |
| Carcass with all<br>tissues | 0.66                                                       | 0.23  | 0.45  | 0.21 | 0.12 | 0.13  | 0.37  | 0.28  |
| Total                       | 102.3                                                      | 100.3 | 103.7 | 99.1 | 91.5 | 110.4 | 96.8  | 96.5  |

Table 7  
Recovery of WR-158,122 (as  $^{14}\text{C}$ ) in Bile Duct Ligated,  
Bile-Duct Cannulated and Control Rats

| Sample                      | In Percent Dose   |           |      |                      |           |       |          |           |      |
|-----------------------------|-------------------|-----------|------|----------------------|-----------|-------|----------|-----------|------|
|                             | Bile-Duct Ligated |           |      | Bile-Duct Cannulated |           |       | Controls |           |      |
|                             | N                 | $\bar{x}$ | SD   | N                    | $\bar{x}$ | SD    | N        | $\bar{x}$ | SD   |
| Urine                       | 10                | 16.34     | 3.78 | 10                   | 2.28      | 1.28  | 8        | 1.55      | 0.81 |
| Bile                        |                   |           |      | 10                   | 10.88     | 6.14  |          |           |      |
| Feces                       | 10                | 81.55     | 5.51 | 10                   | 81.41     | 10.10 | 8        | 98.21     | 5.16 |
| Carcass with<br>all tissues | 10                | 1.98      | 3.24 | 10                   | 1.33      | 0.98  | 8        | 0.31      | 0.18 |
| Total recovery              | 10                | 99.87     | 6.26 | 10                   | 95.91     | 11.10 | 8        | 100.1     | 5.64 |

Table 8

SMA 12/60 Assays on a Bile Duct Cannulated Monkey Prior to Treatment With WR-158, 122<sup>14</sup> C  
(Rhesus 75-5 ♀)

|                                          | Sugar<br>mg % | Uric Acid<br>mg % | Chol<br>mg %  | SGOT<br>mU/ml | LDH<br>mU/ml   | P<br>mg %     | Alk P<br>mU/ml | Ca<br>mg %    | Direct<br>Bili-<br>rubin<br>mg % | Total<br>Bili-<br>rubin<br>mg % | Protein<br>g % | Alb<br>g %    |
|------------------------------------------|---------------|-------------------|---------------|---------------|----------------|---------------|----------------|---------------|----------------------------------|---------------------------------|----------------|---------------|
| Surgery<br>2-15-80                       | 87            | 0.2               | 110           | 45            | 493            | 6.3           | >350           | 10.8          | 0.2                              | 0.5                             | 8.1            | 4.0           |
| 2-25-80<br>7 days after<br>2nd surgery   | 79            | 0.7               | 80            | 40            | 355            | 4.5           | >350           | 9.0           | 0.3                              | 0.5                             | 6.5            | 3.2           |
| 3-7-80<br>3 days before<br>1st treatment | 85            | 0.3               | 80            | 40            | 330            | 5.9           | >350           | 9.8           | 0.2                              | 0.3                             | 7.3            | 3.5           |
| Normal*<br>Values                        | 89<br>+3.5    | 0.61<br>+0.05     | 170.2<br>+6.0 | 30.4<br>+2.2  | 271.2<br>+24.6 | 3.56<br>+0.21 | 166.3<br>+17.5 | 9.78<br>+0.16 | 0.12<br>+0.01                    | 0.26<br>+0.02                   | 8.01<br>+0.13  | 3.77<br>+0.11 |

\* Based on assays of 20 rhesus female monkeys by same laboratory. (mean + S.E.)

Table 9

Blood and Plasma Levels of WR-158,122  
(as  $^{14}\text{C}$ ) in a Bile Duct Cannulated  
Monkey (75-5 ♀)

Single Oral Dose of 5 mg/kg

| Hours Post<br>Dose | First Treatment                    |        |       |
|--------------------|------------------------------------|--------|-------|
|                    | $\mu\text{g/g}$ as $^{14}\text{C}$ |        | Hct   |
|                    | Blood                              | Plasma |       |
| 2                  | 0.33                               | 0.52   | 41    |
| 4                  | 0.26                               | 0.40   | 40    |
| 6                  | 0.17                               | N.S.*  | N.S.* |
| 8                  | 0.13                               | 0.20   | 40    |
| 12                 | 0.05                               | 0.09   | 40    |
| 24                 | 0.02                               | 0.05   | 42    |
| 49                 | <0.01                              | <0.01  | 38    |
| 72½                | <0.01                              | <0.01  | 40    |

\* No sample

Table 10

Cumulative Excretion of WR-158,122 (as  $^{14}\text{C}$ ) in Bile, Urine and Feces  
from a Bile Duct Cannulated Monkey (75-5 ♀)

Single Oral Doses of 5 mg/kg

| First Treatment              |        |       |        |       |        |       |                   |
|------------------------------|--------|-------|--------|-------|--------|-------|-------------------|
| Excretion in Percent of Dose |        |       |        |       |        |       |                   |
| Hours Post<br>Dose           | Bile   |       | Urine  |       | Feces  |       | Combined<br>Total |
|                              | Period | Total | Period | Total | Period | Total |                   |
| 0-12                         | 0.46   | 0.46  | 1.9    | 1.9   |        |       | 2.4               |
| 12-24                        | 0.21   | 0.67  | 0.49   | 2.4   | 48.4   | 48.4  | 51.5              |
| 24-48                        | 0.20   | 0.87  | 0.59   | 3.0   | 36.9   | 85.3  | 89.2              |
| 48-72                        | 0.03   | 0.90  | 0.05   | 3.1   | 1.2    | 86.5  | 90.5              |
| 72-96                        | 0.01   | 0.91  | <0.01  | 3.1   | 0.10   | 86.6  | 90.6              |

| Second Treatment             |        |       |        |       |        |       |                   |
|------------------------------|--------|-------|--------|-------|--------|-------|-------------------|
| Excretion in Percent of Dose |        |       |        |       |        |       |                   |
| Hours Post<br>Dose           | Bile   |       | Urine  |       | Feces  |       | Combined<br>Total |
|                              | Period | Total | Period | Total | Period | Total |                   |
| 0-12                         | 0.26   | 0.26  | 1.5    | 1.5   |        |       | 1.8               |
| 12-24                        | 0.21   | 0.47  | 1.1    | 2.6   | 35.8   | 35.8  | 38.9              |
| 24-48                        | 0.13   | 0.60  | 0.37   | 3.0   | 57.9   | 93.7  | 97.3              |
| 48-72                        | 0.01   | 0.61  | 0.11   | 3.1   | 1.0    | 94.7  | 98.4              |
| 72-96                        | 0.01   | 0.62  | 0.02   | 3.1   | 0.09   | 94.8  | 98.5              |
| 96-120                       | <0.01  | 0.62  | 0.01   | 3.1   | 0.05   | 94.9  | 98.6              |

Table 11

SMA 12/60 Results on Two Control Monkeys Before Treatment

| Monkey No.       | Uric       |               | Chol          | SGOT         | LDH            | P             | Alk. P         | Ca            | Direct        |               | Total | Protein       | Alb           |
|------------------|------------|---------------|---------------|--------------|----------------|---------------|----------------|---------------|---------------|---------------|-------|---------------|---------------|
|                  | Sugar      | Acid          |               |              |                |               |                |               | Bili-rubin    | Bili-rubin    |       |               |               |
|                  | mg %       | mg %          | mg %          | mU/ml        | mU/ml          | mg %          | mU/ml          | mg %          | mg %          | mg %          |       | g %           | g %           |
| 1449 ♀*          | 60         | 0.4           | 205           | 42           | 481            | 3.2           | 235            | 9.3           | 0.0           | 0.1           |       | 7.5           | 3.9           |
| 709 ♀**          | 51         | 0.3           | 170           | 44           | 446            | 2.5           | 151            | 9.6           | 0.0           | 0.1           |       | 7.3           | 3.9           |
| Normal Values*** | 89<br>+3.5 | 0.61<br>+0.05 | 170.2<br>+6.0 | 30.4<br>+2.2 | 271.2<br>+24.6 | 3.56<br>+0.21 | 166.3<br>+17.5 | 9.78<br>+0.16 | 0.12<br>+0.01 | 0.26<br>+0.02 |       | 8.01<br>+0.13 | 3.77<br>+0.11 |

\* assayed 2 days before treatment

\*\* assayed 15 days before treatment

\*\*\* based on assays of 20 rhesus female monkeys by same laboratory (mean ± S.E.)

Table 12

Cumulative Excretion of WR-158,122 in Urine and Feces  
of Two Control Monkeys

Single Oral Doses of 5 mg/kg

| Rhesus 1449 ♀      |        |       |        |       |                   |
|--------------------|--------|-------|--------|-------|-------------------|
| Hours Post<br>Dose | Urine* |       | Feces  |       | Combined<br>Total |
|                    | Period | Total | Period | Total |                   |
| 0-12               | 2.6    | 2.6   | 0.02   | 0.02  | 2.6               |
| 12-24              | 7.8    | 10.4  | 0.17   | 0.19  | 10.6              |
| 24-48              | 2.9    | 13.3  | 51.9   | 52.1  | 65.4              |
| 48-72              | 0.59   | 13.9  | 11.0   | 63.1  | 77.0              |
| 72-96              | 0.15   | 14.1  | 6.9    | 70.0  | 84.1              |

| Rhesus 709 ♀       |        |       |        |       |                   |
|--------------------|--------|-------|--------|-------|-------------------|
| Hours Post<br>Dose | Urine  |       | Feces  |       | Combined<br>Total |
|                    | Period | Total | Period | Total |                   |
| 0-12               | 6.0    | 6.0   | N.S.** |       | 6.0               |
| 12-24              | 8.5    | 14.5  | 0.13   | 0.13  | 14.6              |
| 24-48              | 2.2    | 16.7  | 0.02   | 0.15  | 16.9              |
| 48-72              | 0.71   | 17.4  | 58.3   | 58.5  | 75.9              |
| 72-96              | 0.24   | 17.6  | 10.5   | 69.0  | 86.6              |
| 96-120             | 0.05   | 17.7  | 0.59   | 69.6  | 87.3              |

\* 24 and 48 hr. samples contaminated with menses

\*\* N.S. = No Sample

SIGNATURE PAGE

*Marvin Wilson Tabor*

Marvin Wilson Tabor, Ph.D.  
Acting Principal Investigator  
1980-1981 Contract Period

*Carl C. Smith*

Carl C. Smith, Ph.D.

Distribution list

|           |                                                                                                                                        |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------|
| 12 copies | Director (ATTN: SGRD-UWZ-AG)<br>Walter Reed Army Institute of<br>Research<br>Walter Reed Army Medical Center<br>Washington, D.C. 20012 |
| 4 copies  | HQDA (SGRD-SI)<br>Fort Detrick<br>Frederick, MD 21701                                                                                  |
| 2 copies  | Defense Documentation Center<br>ATTN: DDC-DCA<br>Cameron Station<br>Alexandria, Virginia 22314                                         |
| 1 copy    | Dean<br>School of Medicine<br>Uniformed Services University<br>of the Health Sciences<br>4301 Jones Bridge Road<br>Bethesda, MD 20014  |
| 1 copy    | Superintendent<br>Academy of Health Sciences, U.S. Army<br>ATTN: AHS-COM<br>Fort Sam Houston, Texas 78234                              |

END

DATE  
FILMED

4-8-1

DTIC



| Monkey<br>No.       | Sugar<br>mg % |
|---------------------|---------------|
| 1449 ♀*             | 60            |
| 709 ♀**             | 51            |
| Normal<br>Values*** | 89<br>+3.5    |

\* assayed 2 days before  
 \*\* assayed 15 days  
 \*\*\* based on assay

